US EditionPublished • loading... • Updated
Emergent BioSolutions Inc. (EBS): Analyst Ratings Signal 48.68% Upside Potential
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Emergent BioSolutions Inc. (EBS): Analyst Ratings Signal 48.68% Upside Potential
Emergent BioSolutions Inc. (NYSE: EBS), a prominent player in the healthcare sector, presents an intriguing opportunity for investors with a potential upside of nearly 49% based on current analyst ratings. Specializing in preparedness and response solutions for public health threats, the company’s portfolio includes critical products like NARCAN Nasal Spray and various vaccines and treatments for anthrax, cholera, typhoid fever, and Ebola. Curre…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
